Invivyd, Inc. (IVVD), a commercial-stage biopharmaceutical company, announced completion of participant enrollment in the Phase 3 LIBERTY clinical trial of VYD2311 for the COVID-19 indication.
VYD2311 is an investigational monoclonal antibody or mAb candidate designed to neutralize contemporary virus lineages, especially SARS-CoV-2 or COVID-19. The FDA granted fast-track designation for VYD2311.
LIBERTY is a Phase 3, randomized, double-blind study designed to evaluate the safety, serum virus-neutralizing antibody responses, and pharmacokinetics of VYD2311. This includes an investigational monoclonal antibody treatment, an mRNA COVID-19 vaccine, and the co-administration of VYD2311 with the mRNA vaccine.
The primary endpoint is to assess the side effects and tolerability of the COVID antibody compared to the vaccine over a period of seven days, with evaluations through day six.
The company stated that the Phase 3 trial will compare the safety and tolerability of its investigational COVID-19 mAb VYD2311 with an mRNA COVID-19 vaccine. Additionally, it will investigate the safety and immunological effects of co-administering VYD2311 alongside the mRNA COVID-19 vaccine.
The total enrollment for the trial is approximately 210 participants.
Invivyd expects to report data from the LIBERTY trial in the third quarter of 2026.
IVVD is currently trading at $0.834, down 3.89%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.